Casirivimab

Specification

• Cat#: THA-0142
• Product Name: Casirivimab
• Description: Casirivimab is part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
• Sequences: Not Available
• Molecular Weight: Not Available
• Introduction: Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. This drug is a combination of antibodies derived from humanized VelocImmune mice in addition to blood samples from patients who have recovered from COVID-19. These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape. On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA. Full safety and efficacy data are not yet available, and further evaluation of this investigational therapy will continue.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Not Available

Pharmaceutical Information

• Pharmacodynamics: Casirivimab and imdevimab work to neutralize the spike protein of SARS-CoV-2. In a clinical trial, casirivimab and imdevimab, when given together, reduced COVID-19-related hospitalization or emergency room visits in patients diagnosed with COVID-19 who were at high risk for disease progression within 28 days after treatment. No benefit has been shown in patients already hospitalized due to COVID-19 receiving this combination.
• Targets: Spike glycoprotein